Chemoprevention of breast cancer

被引:0
作者
Jack Cuzick
机构
[1] University of London,John Snow Professor of Epidemiology, Cancer Research UK Centre for Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary’s School of Medicine and Dentistry
来源
Breast Cancer | 2008年 / 15卷
关键词
Breast cancer; Prevention; Tamoxifen; Raloxifene; SERMs; Aromatase inhibitors;
D O I
暂无
中图分类号
学科分类号
摘要
Trials with tamoxifen have clearly shown that the risk of developing oestrogen receptor positive breast cancer can be reduced at a late stage in the natural history with prophylactic agents. About half of the oestrogen receptor positive cases were prevented, but there was no beneficial effect on ER-negative cancers. The current challenge is to find new agents which achieve this or better efficacy but with fewer side effects. Recent results indicate that the SERM raloxifene has similar efficacy to tamoxifen, but leads to fewer endometrial cancers, gynaecologic symptoms, and thromboembolic events. Results for contralateral tumours in adjuvant trials suggest that aromatase inhibitors may be able to prevent up to 70–80% of ER-positive breast cancers, and this is currently being investigated in two large prevention trials, one using anastrozole (IBIS-II) and the other exemestane (MAP.3). New agents are needed, for receptor negative breast cancer and several possibilities are currently under investigation.
引用
收藏
页码:10 / 16
页数:6
相关论文
共 185 条
[1]  
Parkin DM(2005)Global Cancer Statistics, 2002 CA Cancer J Clin. 55 74-108
[2]  
Bray F(2005)Lifetime recreational exercise activity and breast cancer risk among black women and white women J Natl Cancer Inst. 97 1671-9
[3]  
Ferlay J(2006)Adult weight change and risk of postmenopausal breast cancer JAMA. 296 193-201
[4]  
Bernstein L(1976)Risk for breast cancer development determined by mammographic parenchymal pattern Cancer. 37 2486-92
[5]  
Patel AV(1992)The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification Cancer Detect Prev. 16 67-72
[6]  
Ursin G(2003)Wolfe’s parenchymal pattern and percentage of the breast with mammographic densities: redundant or complementary classifications? Cancer Epidemiol Biomarkers Prev. 12 728-32
[7]  
Eliassen AH(1995)Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian national breast screening study J Natl Cancer Inst. 87 670-5
[8]  
Colditz GA(2007)Mammographic density and the risk and detection of breast cancer N Engl J Med. 356 227-36
[9]  
Rosner B(2004)Tamoxifen and breast density in women at increased risk of breast cancer J Natl Cancer Inst. 96 621-8
[10]  
Willett WC(2003)Postmenopausal hormone therapy and change in mammographic density J Natl Cancer Inst. 95 30-7